At the heart of COVID-19

J Card Surg. 2020 Jun;35(6):1287-1294. doi: 10.1111/jocs.14596. Epub 2020 May 5.

Abstract

Coronavirus disease (COVID-19) first presented in Wuhan, Hubei province, China in December 2019. Since then, it has rapidly spread across the world, and is now formally considered a pandemic. The disease does not discriminate but increasing age and the presence of comorbidities are associated with severe form of the disease and poor outcomes. Although the prevalence of COVID-19 in patients with cardiovascular disease is under-reported, there is evidence that pre-existing cardiac disease can render individuals vulnerable. It is thought that COVID-19 may have both a direct and indirect effect on the cardiovascular system; however, the primary mechanism of underlying cardiovascular involvement is still uncertain. Of particular interest is the role of angiotensin-converting enzyme 2, which is well known for its cardiovascular effects and is also considered to be important in the pathogenesis of COVID-19. With a range of different drug candidates being suggested, effective anti-virals and vaccines are an area of on-going research. While our knowledge of COVID-19 continues to rapidly expand, this review highlights recent advances in our understanding of the interaction between COVID-19 and the cardiovascular system.

Keywords: COVID-19; cardiovascular; heart.

Publication types

  • Review

MeSH terms

  • COVID-19
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / epidemiology*
  • China / epidemiology
  • Comorbidity
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / epidemiology*
  • Female
  • Global Health
  • Humans
  • Male
  • Pandemics / prevention & control
  • Pandemics / statistics & numerical data*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / epidemiology*
  • Risk Assessment
  • Survival Analysis